Recombinant human IL-3 (interleukin 3) can promote proliferation, survival, and differentiation of hematopoietic stem cells and committed progenitor cells of the myeloid or megakaryocyte lineage. This includes cells of the basophilic, megakaryocyte, erythroid, eosinophilic, monocytic, and mast cell lineage. Suitable for use in cell culture, functional assays, and differentiation studies, the recombinant human IL-3 is ideal for research.
Applications
Human IL-3 can be used for a variety of applications, including:
Induction of colony formation from hematopoietic progenitor cells in semi-solid medium in vitro , for example, CD34+ cells from umbilical cord blood2 .
In vitro differentiation studies, for example, of B lymphoid progenitors3 .
Cultivation of plasmacytoid dendritic cells4 .
In vitro expansion of hematopoietic stem cells.
Investigation of mast cell or basophil function, for example, basophil interaction with blood vessels5 .
Investigation of IL-3–mediated signaling pathways.
Background information
Interleukin 3 (IL-3) is a hematopoietic growth factor, which is produced mainly by activated T cells, but is also secreted by other cell types, including mast cells, eosinophils, and keratinocytes. The broad spectrum of biological activities of IL-3 includes the stimulation of the proliferation and differentiation of immature pluripotent hematopoietic stem cells and various lineage-committed progenitor cells, leading to the production of most of the major blood cell types. In addition, IL-3 also affects the functional activity of mature mast cells, basophils, eosinophils, and macrophages.
Quality description
Research-grade
cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.
Premium-grade
cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific certificates of analysis are available on request (macstec@miltenyibiotec.de).
from Miltenyi Biotec (MB) in comparison to recombinant human IL-3 from a different supplier (S), both under reducing and non-reducing conditions.
SDS-PAGE of Human IL-3, premium grade
from Miltenyi Biotec (MB) in comparison to recombinant human IL-3 from a different supplier (S), both under reducing and non-reducing conditions.
Selected references
Kitamura, T. et al. (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140: 323-334
IL-3 increases production of B lymphoid progenitors from human CD34
+
CD38
–
cells.
J. Immunol. 165: 2382-2389
Tas, S. W. et al. (2007) Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110: 1540-1549
Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments
in vitro
.
Haematologica 95(4): 542-550
Narla, A. et al. (2011) Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood 118(8): 2296-2304
Steinleitner, K. et al. (2012) EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages. Anticancer Res. 32(11): 4883-4889
Optimized generation of functional neutrophils and macrophages from patient-specific induced pluripotent stem cells:
ex vivo
models of X
0
-linked, AR22
0
- and AR47
0
- chronic granulomatous diseases.
Biores Open Access 3(6): 311-326
Dighe N. et al. (2014) Long-term reproducible expression in human fetal liver hematopoietic stem cells with a UCOE-based lentiviral vector. PLoS One 9(8): e104805
Laurenti, E. et al. (2015) CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 16(3): 302-313
View details 
